Notably, two of the 12 patients exhibited increased PD-L1 expression following ONCOS-102 administration and developed systemic anti-tumor immunity, as evidenced by melanoma-associated antigen 3 (MAGE-A3)-specific CD8 + T cells and New York oesophageal squamous cell carcinoma 1 (NY-ESO-1)-specific CD8 + T cells [149]. This evidence concerns the gene MAGEA3 and neoplasm.